Ruzica Z Conic1, Claudia I Cabrera1, Alok A Khorana2, Brian R Gastman3. 1. Department of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, Ohio. 2. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio. 3. Department of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, Ohio. Electronic address: gastmab@ccf.org.
Abstract
BACKGROUND: The ideal timing for melanoma treatment, predominantly surgery, remains undetermined. Patient concern for receiving immediate treatment often exceeds surgeon or hospital availability, requiring establishment of a safe window for melanoma surgery. OBJECTIVE: To assess the impact of time to definitive melanoma surgery on overall survival. METHODS: Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (N = 153,218). The t test and chi-square test were used to compare variables. Cox regression was used for multivariate analysis. RESULTS: In a multivariate analysis of patients in all stages who were treated between 90 and 119 days after biopsy (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.18) and more than 119 days (HR, 1.12; 95% CI, 1.02-1.22) had a higher risk for mortality compared with those treated within 30 days of biopsy. In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days (HR, 1.05; 95% CI, 1.01-1.1), 60 to 89 days (HR, 1.16; 95% CI, 1.07-1.25), 90 to 119 days (HR, 1.29; 95% CI, 1.12-1.48), and more than 119 days after biopsy (HR, 1.41; 95% CI, 1.21-1.65). Surgical timing did not affect survival in stages II and III. LIMITATIONS: Melanoma-specific survival was not available. CONCLUSION: Expeditious treatment of stage I melanoma is associated with improved outcomes.
BACKGROUND: The ideal timing for melanoma treatment, predominantly surgery, remains undetermined. Patient concern for receiving immediate treatment often exceeds surgeon or hospital availability, requiring establishment of a safe window for melanoma surgery. OBJECTIVE: To assess the impact of time to definitive melanoma surgery on overall survival. METHODS:Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (N = 153,218). The t test and chi-square test were used to compare variables. Cox regression was used for multivariate analysis. RESULTS: In a multivariate analysis of patients in all stages who were treated between 90 and 119 days after biopsy (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.18) and more than 119 days (HR, 1.12; 95% CI, 1.02-1.22) had a higher risk for mortality compared with those treated within 30 days of biopsy. In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days (HR, 1.05; 95% CI, 1.01-1.1), 60 to 89 days (HR, 1.16; 95% CI, 1.07-1.25), 90 to 119 days (HR, 1.29; 95% CI, 1.12-1.48), and more than 119 days after biopsy (HR, 1.41; 95% CI, 1.21-1.65). Surgical timing did not affect survival in stages II and III. LIMITATIONS: Melanoma-specific survival was not available. CONCLUSION: Expeditious treatment of stage I melanoma is associated with improved outcomes.
Authors: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Caroline G Watts; Anne E Cust; Scott W Menzies; Elliot Coates; Graham J Mann; Rachael L Morton Journal: JAMA Dermatol Date: 2015-02 Impact factor: 10.282
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: Alexander J Stratigos; Maria Concetta Fargnoli; Arcangela De Nicolo; Ketty Peris; Susana Puig; Efthymia Soura; Chiara Menin; Donato Calista; Paola Ghiorzo; Mario Mandala; Daniela Massi; Monica Rodolfo; Laura Del Regno; Irene Stefanaki; Helen Gogas; Veronique Bataille; Margaret A Tucker; David Whiteman; Eduardo Nagore; Maria Teresa Landi Journal: J Eur Acad Dermatol Venereol Date: 2018-09-14 Impact factor: 6.166
Authors: M Kiuru; Q Li; G Zhu; J R Terrell; K Beroukhim; E Maverakis; T H M Keegan Journal: J Eur Acad Dermatol Venereol Date: 2022-08-23 Impact factor: 9.228
Authors: Smita C Banerjee; Andrew Sussman; Elizabeth Schofield; Dolores D Guest; Yvonne S Dailey; Matthew R Schwartz; David B Buller; Keith Hunley; Kimberly A Kaphingst; Marianne Berwick; Jennifer L Hay Journal: J Health Commun Date: 2021-10-06
Authors: Cimarron E Sharon; Andrew J Sinnamon; Michael E Ming; Emily Y Chu; Douglas L Fraker; Giorgos C Karakousis Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282
Authors: Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore Journal: Clin Oncol Res Date: 2020-06-26